New Multiple Myeloma Drug Shows Promising Results In Trial
There may be a new drug with promising recovery results for multiple myeloma patients.
It’s called daratumumab. During a recent clinical trial, of the patients who took the drug, 43 percent didn’t see any trace of the rare blood cancer afterwards compared to the 19 percent who took a standard drug duo.
With daratumumab, the risk of dying or advancing the cancer decreased by 63 percent over 13.5 months, according to the study, which was published in the New England Journal of Medicine.
For each of the patients, at some point, the cancer didn’t respond to previous treatment or returned altogether. The study’s researchers say the drug’s results are “unprecedented.”